BioMarin Pharmaceutical Inc. (BMRN) is a Healthcare stock trading at $54.70 (as of 2026-06-18), with a market capitalization of $10.31B and a trailing P/E of 40.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
BioMarin Pharmaceutical Inc. develops and markets treatments for people with serious, life-threatening rare diseases and medical conditions. Its products include therapies such as enzyme replacement and related approaches for disorders including MPS IV, MPS VI, ceroid lipofuscinosis type 2, and phenylketonuria, along with treatments for achondroplasia and other targeted indications.